What is the drug of choice for uncomplicated enteric (typhoid) fever in an adult patient without known drug allergies?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Drug of Choice for Enteric Fever

Azithromycin 20 mg/kg/day (maximum 1g/day) orally for 7 days is the preferred first-line treatment for uncomplicated enteric fever in adults, particularly in regions with high fluoroquinolone resistance. 1, 2

Treatment Selection Algorithm

For Mild to Moderate Uncomplicated Cases (Outpatient or Non-Severe)

  • Azithromycin is the drug of choice with demonstrated 94% cure rate, lower risk of clinical failure (OR 0.48,95% CI 0.26-0.89) compared to fluoroquinolones, and shorter hospital stays (-1.04 days) 3, 1, 2, 4

  • Azithromycin shows significantly lower relapse rates (OR 0.09,95% CI 0.01-0.70) compared to ceftriaxone 3, 2, 4

  • Dosing: 20 mg/kg/day (maximum 1g/day) orally for 7 days 1, 2

For Severe Cases Requiring Hospitalization

  • Ceftriaxone 50-80 mg/kg/day (maximum 2g/day) intravenously for 5-7 days is first-line for hospitalized patients with severe disease 1, 2

  • Ceftriaxone may result in faster fever clearance (0.52 days shorter time to defervescence) compared to azithromycin 2, 5

  • In culture-confirmed cases, ceftriaxone showed lower risk of treatment failure (HR 0.24,95% CI 0.08-0.73) compared to gatifloxacin 3, 2

Alternative Options Based on Resistance Patterns

Fluoroquinolones (ciprofloxacin, ofloxacin):

  • Should be reserved for fully susceptible S. typhi strains only 1, 6
  • Avoid empiric use in cases from South Asia due to >70% resistance rates 1
  • Ciprofloxacin is FDA-approved for typhoid fever but resistance is essentially a class effect and increasing globally 1, 7

Cefixime:

  • Oral option at 8 mg/kg/day as single daily dose for 7-14 days 1
  • May have higher clinical failure rates compared to fluoroquinolones (RR 13.39,95% CI 3.24-55.39) and longer time to defervescence (MD 1.74 days) 5
  • Not preferred over azithromycin or ceftriaxone 5, 8

Critical Management Steps

Initial Diagnostic Approach

  • Always obtain blood cultures before initiating antibiotics whenever possible 1, 2, 6

  • For patients with sepsis features, initiate broad-spectrum therapy immediately after culture collection, then narrow based on susceptibility results 1, 2

Monitoring and Expected Response

  • Expected fever clearance within 4-5 days of appropriate therapy 1

  • Switch from parenteral to oral therapy once temperature normal for 24 hours and clinical improvement occurs 1

  • Total treatment duration: 7 days for most uncomplicated cases 1, 2

Common Pitfalls to Avoid

  • Do not use ciprofloxacin empirically without susceptibility data, especially for infections acquired in South Asia where resistance exceeds 70% 1

  • Do not rely on older first-line agents (chloramphenicol, ampicillin, co-trimoxazole) as empiric therapy due to widespread multidrug resistance 3, 9

  • Always modify therapy when susceptibility results become available rather than continuing empiric coverage 2, 6

  • Chloramphenicol should only be considered as last-resort when no other options available 1

Resistance Context

The recommendation for azithromycin as first-line reflects the current global resistance landscape where fluoroquinolone resistance is widespread, particularly in South Asia 1, 8. While older WHO guidelines from 2003-2012 recommended fluoroquinolones as first-line 3, more recent evidence demonstrates azithromycin's superiority in populations with drug-resistant strains 3, 4. The 2024 WHO Essential Medicines guidelines now reflect this shift based on systematic review evidence 3.

References

Guideline

Treatment of Enteric Fever in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Enteric Fever

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins.

The Cochrane database of systematic reviews, 2022

Guideline

Cefpodoxime in Enteric Fever

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever).

The Cochrane database of systematic reviews, 2011

Research

Study of clinical profile and antibiotic response in typhoid fever.

Indian journal of medical microbiology, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.